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http://dx.doi.org/10.1016/j.jfma.201Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western coun-
tries, and has become increasingly recognized as a public health problem in Taiwan. Patients
with non-alcoholic steatohepatitis, a more severe form of NAFLD, may progress to cirrhosis and
its related complications, including hepatocellular carcinoma. Since NAFLD is highly linked to
metabolic syndrome, such patients may have increased risks of complications related to both
liver disease and metabolic syndrome. Therefore, if we fail to cope with this growing health
problem, NAFLD may gradually replace viral hepatitis as the major etiology of liver disease
in Taiwan.
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Non-alcoholic fatty liver disease (NAFLD), which describes
a condition of fat accumulation in the liver in the absence
of excessive alcohol consumption and specific causes of
hepatic steatosis,1 is the most common liver disorder in the
world, affecting 20e40% of the general population in
Western countries and 5e40% in the general population
across the Asia-Pacific region.2,3 The prevalence of NAFLD,
including the more aggressive non-alcoholic steatohepatitis
(NASH), is increasing in parallel with the growing pandemics
of obesity, type 2 diabetes mellitus (T2DM), and metabolic
syndrome.4 A certain proportion of NASH patients progress
to cirrhosis and its related complications, such as hepato-
cellular carcinoma (HCC).5 Previous studies showed that
10e29% of NASH patients may develop cirrhosis within 10
years,6 and 4e27% of these cirrhosis patients may have
HCC4 (Fig. 1). Therefore, NAFLD/NASH will gradually
become the major etiology of chronic liver disease
worldwide.
Large population-based surveys in the Asia-Pacific region
indicated that the prevalence rates of NAFLD range from
12% to 24% in population subgroups, depending on age,
gender, ethnicity, and geographic location (urban vs. rural).
In Taiwan, the prevalence of NAFLD is about 11.4e41% in
two studies,7,8 and the rates are higher in population
subgroups, from 66.4% in healthy taxi drivers9 to 80% in
obese individuals who attended weight reduction
programs.10 Although viral hepatitis continues to rage in
Taiwan, the health impact of NAFLD has become increas-
ingly recognized, and is likely to be a huge disease burden10-29% in 10 years 
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Figure 1 Natural history of nonalcoholic fatty liver disease
(NAFLD). NAFLD affects 20e40% of the general population in
Western countries and 5e40% across the Asia-Pacific region.
The prevalence of its more aggressive form, nonalcoholic
steatohepatitis (NASH), is about 6e13%. About 10e29% of NASH
patients progress to cirrhosis within 10 years, 40e62% of them
develop a complication of cirrhosis, and 4e27% of patients with
NASH-related cirrhosis may have hepatocellular carcinoma
(HCC) over time.in the future. Therefore, it is time for us to formulate
strategies in advance to cope with this growing health
problem.Diagnosis of NAFLD
Fatty liver or hepatic steatosis is characterized by triglyc-
eride accumulation within the cytoplasm of hepatocytes,
and includes a spectrum of liver disease from a benign
simple steatosis, steatohepatitis, to fibrosis, and may
progress to liver cirrhosis, liver failure, and hepatocellular
carcinoma.11 Several conditions have been linked to fatty
liver. Among them, alcoholic liver disease and NAFLD are
most common.
NAFLD is a more widely used term than “non-alcoholic
steatohepatitis,” which was originally developed by Ludwig
in 1979 to describe an alcoholic-like liver disease in
patients who do not drink alcohol12,13 on the basis of
histological findings. Patients with NAFLD usually have
slightly elevated liver enzyme values, deny excessive
alcohol consumption, and have negative laboratory tests
suggestive of viral hepatitis, autoimmune liver disease, and
congenital causes of chronic hepatitis.
Although fatty liver may be identified by imaging
modalities including ultrasonography, computed tomog-
raphy (CT), and magnetic resonance imaging with
a reasonably high sensitivity (w80% for 30% steatosis),14
steatohepatitis and fibrosis cannot be judged merely on
image findings. Several new imaging modalities and
biomarkers are emerging and may provide more detailed
information about hepatic tissue or even replace biopsy,
although most of them are not available on clinical prac-
tice, are expensive, need further validation, and remained
research tools up to now.1,15,16 Accordingly, liver histology
remains the gold standard for the diagnosis of NAFLD/
NASH.12,16,17 Because it is often impractical to use a path-
ological definition in clinical practice and research studies,
an operational definition of NAFLD has been proposed in the
Asia-Pacific region.18
According to the proposed Asian Pacific Association for
the Study of Liver operational definition, fatty liver can be
defined by the presence of at least two of three abnormal
findings on abdominal ultrasonography: diffusely increased
echogenicity (“bright”) liver with liver echogenicity greater
than kidney or spleen, vascular blurring, and deep attenu-
ation of ultrasound signal. NAFLD is highly likely provided
that the other causes of liver disease have been rigorously
ruled out, particularly significant alcohol intake (more than
140 g weekly in men, 70 g weekly in women), hepatitis B,
hepatitis C, and medication use. Alternatively, in patients
with otherwise unexplained alanine aminotransferase (ALT)
elevation, NAFLD is highly likely to be the cause if hepatic
imaging results compatible with fatty liver, and metabolic
risk factors are also present. However, in some clinical
settings, liver biopsy is usually the first-line procedure for
the diagnosis of NAFLD, such as in cases whose diagnosis are
uncertain, who are at risk of advanced hepatic fibrosis (in
the absence of clinical or imaging evidence of cirrhosis), or
had both chronic liver diseases other than NAFLD and
metabolic risk factors, or enrolled in clinical trials, or
subjected to laparoscopy for another purpose (because of
NAFLD in Taiwan 529reduced risk and greater convenience, e.g., cholecystec-
tomy, gastric banding),18 or during elective surgical
procedure (such as anti-obesity surgery).16 On the other
hand, liver biopsy should not be performed in patients with
recent weight change. A watchful period (4e6 months) is
useful, aimed at enforcing diet and lifestyle measures. If
these measures failed in weight loss, ALT normalization,
and a reduction of insulin resistance (IR), liver biopsy
should be considered after balancing the risk for advanced
fibrosis (age, diabetes, IR), patient motivation, and
competing comorbidities.16
Prevalence, clinical significance, and risk
factors of NAFLD worldwide
With the rising prevalence of obesity and T2DM worldwide,
NAFLD has become a major public health problem.19
Although NAFLD and NASH are now considered to be
common causes of chronic liver disease, an increasing
indication for liver transplantation and a possible cause of
HCC,12 it is difficult to determine the true prevalence of
NAFLD worldwide because of the problematic interpreta-
tion of data from various studies, such as referral bias,
population heterogeneity, study design, imaging modalities
used, and use of liver biopsies. On the basis of hepatic
imaging and/or quantification of hepatic triglyceride
content, the prevalence of fatty liver disease in Western
countries is estimated to be 24e42%, depending on gender
and ethnicity,12,13 and is higher in population subgroups,
such as 80% in obese individuals.20 Of particular note, about
3e15% of the general population has NASH.
Risk factors associated with the development of NAFLD
include older age, obesity, T2DM, as well as dyslipidemia.21
Therefore, NAFLD was conceptualized as a part of meta-
bolic syndrome (MetS).12,13,22,23 However, the association
of NAFLD with metabolic risk factors is only evident when
regional definitions of anthropometry are used.
NAFLD in the Asia-Pacific region
In the past, NAFLD has been thought to be uncommon in the
Asia-Pacific region because it was considered a disorder of
affluence, and in this region the burden of viral hepatitis is
huge.2,3 However, the major risk factors for NAFLD, like
glucose intolerance and T2DM, obesity, dyslipidemia, and
metabolic syndrome, are widely prevalent in the Asia-
Pacific region and increasing in geometric propor-
tions.19,24 Therefore, recent surveys by using ultrasonog-
raphy indicated that the prevalence of NAFLD in the
general population across Asia-Pacific region varies from 5%
to 30%.20 In addition, a study from Japan demonstrated
a 2.4-fold increasing prevalence of fatty liver over a 12-
year period,25 an implication that the prevalence is
indeed increasing in this region.
Prevalence and risk factors of NAFLD in Taiwan
Although some studies use laparoscopy or liver biopsy to
diagnose NAFLD in obese patients,26,27 the diagnostic
criteria for NAFLD among most epidemiologic studies inTaiwan are based on the history without excessive alcohol
intake, chronic viral hepatitis, as well as known etiologies
of liver disease and ultrasonographic findings consistent
with fatty liver (Table 1).7e10,24,26,28,30e32,40,50,51 Several
studies on the general population and those undergoing
a health checkup showed the prevalence of NAFLD, ranging
from 11.4% to 41% in Taiwan.7,8 The prevalence is higher in
population subgroups, from 66.4% among 1635 volunteer
healthy taxi drivers (1541 males and 94 females)9 to 80% in
210 apparently healthy obese individuals who attended
weight reduction programs.10 In adolescents, the preva-
lence of NAFLD increased progressively from 16.0% in the
normal group to 50.5% in the overweight group, and 63.5%
among obese individuals.28
On the other hand, in a general population study that
included 11.4% (372/3260) individuals with elevated ALT,
NAFLD appears to be the most common cause of ALT
elevation and presumed liver injury in Taiwan, with
a prevalence of 33.6%, and followed by HBV (28.5%),
unexplained cause (21.8%), HCV (13.2%), both HBV and HCV
(2.2%), and excess alcohol consumption (0.8%). In addition,
the prevalence of ALT elevation in NAFLD was 18.1% (125/
691) in adults29 and 23.3% (20/86) in adolescents.28
Risk factors associated with the presence of NAFLD in
Taiwan have been examined in the general population, obese
persons, or individuals who received laparoscopy, and male
gender, older age, BMI, obesity, waist circumference, dia-
betes, hypercholesterolemia, hypertriglyceridemia, hyper-
tension, elevated ALT, homeostasismodel assessment-insulin
resistance (HOMA-IR), and hyperuricemia are the identified
risk factors.7,10,28,30,31 Of patients with metabolic disorders,
waist circumference and IR are independently associated
with fatty liver in obese individuals,10 and only hyper-
triglyceridemia was related to NAFLD in non-obese individ-
uals. In addition, presence of MetS, high blood pressure, and
high fasting glucose are independent factors related to an
increased risk of NASH.26
Therefore, the development of NAFLD in Taiwan is
closely associated with metabolic derangements, as
observed in other Asian countries. Metabolic disorders are
also related to ALT elevation in patients without known
etiologies of liver disease.NAFLD and HCV in Taiwan
As hepatic steatosis is a well-known feature for patients
with HCV infection and may affect disease progression and
therapeutic response of antiviral therapy for Western
chronic hepatitis C (CHC) patients, it is thus important and
interesting to know the impact of hepatic steatosis on
Taiwanese CHC patients. To this end, Liu et al32 enrolled 95
naive Taiwanese patients infected with either hepatitis C
virus (HCV) genotype 1 (n Z 57) or 2 (n Z 38), receiving
interferon alone (n Z 41) or in combination with ribavirin
(n Z 54) therapy, and had available liver histological data.
In their study, about 44 (46%) patients had steatosis and
four (4%) patients had steatohepatitis. They demonstrated
the associations of steatosis and hyperglycemia (pZ 0.01),
hypertriglyceridemia (pZ 004), as well as body mass index
27 (pZ 0.009), while not with HCV genotype or viral load.
Of note, the grade of steatosis correlated well with the
Table 1 NAFLD studies in Taiwan.
Key issue Authors (year) Case number Diagnosis What is known Reference
Prevalence and
Risk factors
Hsiao et al (2004) 210 Ultrasonography plus elevation
of serum ALT levels
The prevalence of NAFLD was 20.5% in obese patients.
Both insulin resistance and ferritin elevation were
significantly associated with NAFLD in obese patients.
10
Lin et al (2005) 187 (33 with
NAFLD)
Ultrasonography plus elevation
of serum AST and ALT levels
The HFE mutations may not contribute to iron
accumulation in CHC or NAFLD patients in Taiwan.
8
Chen et al (2006) 3245 Ultrasonography and history NAFLD is closely associated with elevated ALT, obesity,
diabetes mellitus, hypercholesterolemia,
hypertriglyceridemia, and hyperuricemia. Serum ALT level
was not a good predictor in individuals with NAFLD.
7
Huang et al (2007) 111 Laparoscopic bariatric surgery MetS and NASH were common in severely obese Taiwanese
adults. Presence of MetS, high blood pressure, and high
fasting glucose increased the risk of NASH.
26
Fan et al (2008) 126 Laparoscopic bariatric surgery Laparoscopic inspection of the abdominal cavity provides
important and additional information for the final
diagnosis of chronic liver diseases and detection of
possible pathology in patients.
24
Fu et al (2009) 220 Ultrasonography and testing
negative for serum HBsAg
and anti- HCV antibody
Obesity, ALT abnormality and elevated non-HDL-
cholesterol are risk factors for NAFLD in adolescents.
However, ALT alone is not a sufficient indicator; and
ultrasonography of the liver should be part of the routine
health examination of obese adolescents.
28
Tung et al (2011) 1635 Ultrasonography Gender-related differences of NAFLD. Hypertension,
hyperuricemia, higher AST, higher ALT,
hypertriglyceridemia, and higher fasting plasma glucose
were significantly related to NAFLD in males but not
related to NAFLD in females.
9
Risk factors of NAFLD include male gender, older age, BMI,
obesity, waist circumference, diabetes,
hypercholesterolemia, hypertriglyceridemia,
hypertension, elevated ALT, homeostasis model
assessment-insulin resistance (HOMA-IR) and
hyperuricemia.
7,10,26,28,30,31
NAFLD and HCV Liu et al (2005) 95 Pathology Hepatic steatosis in Taiwanese patients with CHC was
associated with metabolic syndrome, but not with HCV
genotype, advanced fibrosis or the response to antiviral
therapy.
32
Pathophysiologic
studies
Chu et al (2007) 144 (94 with
NAFLD)
Ultrasonography Modest correlations between plasma levels of TNF-alpha
with ALT and triglyceride, and NAFLD patients with
abnormal ALT had significantly higher plasma TNF-alpha
levels than controls.
40
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NAFLD in Taiwan 531number of MetS parameters (pZ 0.018), but not with lower
sustained response rate. And the improvement of steatosis
after treatment (n Z 19) did not correlate with HCV
genotype (p Z 0.850) or sustained response to antiviral
therapy (p Z 0.246). Therefore, they concluded that
hepatic steatosis in Taiwanese patients with CHC was
associated with features of the metabolic syndrome, but
did not correlate with HCV genotype, advanced fibrosis, or
the response to antiviral therapy.32
Pathogenesis of NAFLD
In the traditional “two hit” model of NASH pathogenesis,
steatosis (the “first hit”) will sensitize the liver to the
“second hit,” such as oxidative stress, cytokines, free fatty
acids, as well as endoplasmic stress, and then leads liver to
inflammation, fibrosis, and ultimately cirrhosis.33 However,
because all of these “second hits” can contribute to both
steatosis and progressive liver disease, current lines of
evidence have implied that steatosis may be a part of the
liver’s early adaptive response to stress, rather than
a prerequisite “hit,” and the “second hit,” oxidative stress,
free fatty acids, endoplasmic stress, as well as cytokines
are the true “hit.”33e35 Therefore, in consideration of the
mechanisms of cellular injuries and fibrosis in NAFLD
patients, the “second hit” deserves much more attention.
Accordingly, many hepatic and extrahepatic mediators
have been identified to play important roles in the devel-
opment of inflammation and fibrosis of NASH/NAFLD
patients.16 Some of them are produced directly as results of
steatosis, hepatocyte injury, and apoptosis, such as IR,36
reactive oxygen species, and cytokines, or derived from
Kupffer cell, T-cell, hepatic stellate cells, and other
inflammatory cells37; meanwhile, others are released indi-
rectly as a response to hepatocyte injury or gut-derived
bacterial products,38 including lipopolysaccharide and adi-
pocytokines.39 Since all of them are potentially therapeutic
targets for NAFLD, studies focusing on these mediators and
mechanisms have increased dramatically and worldwide in
recent decades.
Pathophysiologic studies of NAFLD in Taiwan
Several studies in Taiwan have also examined the patho-
physiologic mechanisms of NAFLD. For example, Chu et al40
compared the differences of proinflammatory cytokines, IL-
6, and IL-8, as well as disease severity between 94 NAFLD
patients and 50 matched controls. They found that,
compared with control group, NAFLD patients had signifi-
cantly higher BMI (p < 0.001), fasting sugar (p Z 0.002),
cholesterol (pZ 0.017), and triglyceride (p < 0.001) level.
NAFLD patients with abnormal serum ALT had higher plasma
IL-8 levels (42.87  16.58 pg/mL) than control groups
(9.19  1.75 pg/mL, p Z 0.028), but with comparable
plasma IL-6 levels.40 In addition, the authors also evaluated
the role of TNF-alpha in the pathogenesis of NAFLD and
demonstrated differential plasma TNF-alpha levels
between NAFLD and healthy individuals. They found that
there were modest correlations between plasma levels of
TNF-alpha with ALT (r Z 0.25, p < 0.005) and triglyceride
(r Z 0.40, p < 0.001), and NAFLD patients with abnormal
532 C.-S. Hsu, J.-H. KaoALT had significantly higher plasma TNF-alpha levels than
controls (2.63  0.44 vs. 1.56  0.10 pg/mL, p Z 0.016).41
On the other hand, Lin et al8 examined HFE mutations
and iron accumulation among 125 healthy individuals, 29
patients with CHC, and 33 patients with NAFLD in Taiwan.
They found that all the enrolled participants were free
from C282Y mutation, and the distributions of H63D muta-
tion were comparable among healthy individuals, the CHC
group, and the NAFLD group. Although 34.48% of CHC
patients and 36.36% of NAFLD patients had increased serum
iron store, there was no significant difference in the prev-
alence of HFE mutations between patients with increased
serum iron store and those without in CHC or NAFLD group.
Therefore, they concluded that HFE mutations may not
contribute to iron accumulation in the CHC or NAFLD group
even when serum iron overload is observed in more than
one-third of these patients in Taiwan.8
Recently, Hsiao et al42 studied the beneficial effects of
pioglitazone in NAFLD patients by using a high fat diet mice
model and demonstrated the diminished oxidative damage
of pioglitazone in “NAFLD” mice. They found that the high-
fat diet induced hepatic steatosis may be improved by
adding pioglitazone. Moreover, the increased oxidative
stress and DNA damage, such as increased malondialdehyde
concentration and 8-oxoG staining in the high-fat diet
group, were attenuated by pioglitazone, and decreased
gene expressions of antioxidant defense mechanismdSod1,
Sod2, Ogg1, and MutY in the high-fat diet groupdwere
reversed by pioglitazone coadministration.42
In addition, different kinds of animal models were used
to explore the pathophysiologic mechanisms of NAFLD in
Taiwan. For examples, Lin et al. studied the mechanisms
that androgen/androgen receptor signaling regulates
insulin sensitivity in hepatic androgen receptor-knockout
mice 43. Yeh et al44 examined the effects of high energy
infusion and insulin treatment in diabetic rats. Chen et al45
examined the effects of Metformin on gene expression and
post-translational processing in laying hens. Amali et al46
used TAA-treated zebrafish as a model of steatohepatitis,
and Her et al47 also used zebrafish to study the link between
gankyrin, microRNAs, and liver steatosis. Interestingly, soft-
shelled turtle was also used to examine the effect of die-
tary highly unsaturated fatty acids on lipid peroxidation of
muscle and liver tissues in Taiwan.48Assessment and management of NAFLD
patients
Because of the possibility of disease progression and a close
link with metabolic syndrome, patients with NAFLD should
be monitored for the changes in liver disease severity,
components, and complications of the MetS.15,18 Therefore,
several assays need to be used for the evaluation of liver
function and complications of cirrhosis, such as ALT,
platelet count, serum albumin, bilirubin, and prothrombin
time. Abdominal ultrasonography may also be performed
for the surveillance of HCC, particularly in patients with
NASH-related cirrhosis (cryptogenic cirrhosis). Neverthe-
less, more studies are required to determine the benefit
and cost-effectiveness of HCC surveillance in NAFLD
patients. In addition, insulin resistance (HOMA-IR) score,which is calculated by serum glucose (mg/dL 
0.05551)  serum insulin (mU/L) divided by 22.5),49 and
complications of MetS are required for screening and
assessment, such as waist circumference (central obesity
for Asian criteria), body height and weight (BMI), fasting
blood glucose, serum lipids, blood pressure, and oral
glucose tolerance test (if fasting blood glucose is
S5.6 mmol/L, no history of diabetes).15
The rationale for NAFLD/NASH treatment is to prevent or
reverse hepatic injury induced by lipotoxicity.16 Although
the best management strategy for NAFLD is yet to be
defined, two strategies have been proposed at the 2009
European Association for the Study of the Liver meeting. The
first strategy is to correct IR and hyperinsulinemia as well as
reduce visceral adiposity, and the second is to prevent or
reverse hepatic cellular injury.16 For the first strategy,
weight loss, physical exercise, diet changes, reduction of
sedentary lifestyle, insulin-sensitizing agents, and anti-
obesity surgery are options, while lifestyle measures
including diet control and increasing physical activity such as
aerobic exercise are the first-line treatment and mainstay of
management recommended by the Asia-Pacific Working
Party on NAFLD.18 Accordingly, some weight reduction is
usually required, and even limited physical activity more
than none or any increase over baseline in physical exercise
is preferable. Although the minimal amount of weight loss
and physical activity has not been determined, targets
supported by several International Societies for diabetes
prevention could be applied in NAFLD/NASH patients.
Ideally, the best regimen for NAFLFD/NASH is a long-term,
multidisciplinary, and personalized approach,50 while the
most effective regimen and long-term adherence remain
unclear and need future studies.18
The role of pharmacotherapy remains investigational
and is not recommended for clinical practice. Specific
pharmacological treatment is not recommended for NAFLD
patients, but identified metabolic risk factors, such as
diabetes mellitus and dyslipidemia, should be treated and
screened for regularly. For example, use of statins to treat
hypercholesterolemia is safe and recommended. Obese
patients who do not respond to attempted lifestyle
measures should be referred to centers specializing in
obesity management. In those refractory to medical
measurements, consideration should be given to bariatric
surgery or gastric ballooning.15,18 For specific liver-directed
therapy to prevent or reverse hepatic cellular injury, as
there is still no approved medication for NAFLD/NASH, all
these liver-directed therapies should be considered exper-
imental for now and need to be further examined especially
for their long-term effects on histological endpoints and
safety in the near future.Managements studies for NAFLD in Taiwan
In Taiwan, two studies examined the effects of treatments
on patients with ultrasound-diagnosed NAFLD.51,52 First,
Wang et al51 evaluated the safety and effectiveness of
rosiglitazone in 68 inadequately controlled type 2 diabetes
patients with NAFLD, and found that it was reasonably well
tolerated and might improve one-third of patients’ liver
function after treatment. In their study, only two (2.9%)
NAFLD in Taiwan 533patients discontinued the treatment due to increase of
aspartate aminotransferase (AST) or ALT levels to more
than three times the upper limit of normal, and among the
60 patients who completed the study treatment, mean
fasting plasma glucose, A1C, fasting plasma insulin, mean
ALT, and HOMA-IR were all significantly reduced, whereas
body weight was increased by a mean of 2.6  2.4 kg
(p < 0.001). In addition, 20 (33.3%) patients maintained
their normal AST and ALT levels for at least three consec-
utive measurements and through the end of the study
period. Second, Chen et al investigated the effects of
varied therapeutic lifestyle programs on 54 patients with
ultrasound-diagnosed NAFLD. They divided the participants
into three groupsd(1) diet plus exercise group (nZ 16), (2)
exercise group (n Z 23), (3) control group (n Z 15) dand
found that both 10-week diet-plus-exercise and exercise-
only therapeutic lifestyle programs are effective for
improving anthropometric indices, insulin sensitivity,
ultrasound findings, and physical fitness in NAFLD patients.
However, only the diet-plus-exercise program resulted in
significant improvement in liver biochemistry.52Perspectives
The prevalence of NAFLD in Taiwan is similar to other Asian
countries. Along with the increasing trends in westernized
lifestyle (including overnutrition, sedentary lifestyle),
obesity, diabetes mellitus, as well as metabolic syndrome,
a further increase in the clinical significance of NAFLD/
NASH is anticipated. Of particular note is that NASH, albeit
mild and slowly progressive, indeed exists in Taiwan.53
Therefore, after the control of chronic hepatitis B and C,
NAFLD/NASH will become the most prominent liver disease
and prophylactic measure, and active management strat-
egies should be planned and implemented in time. Unfor-
tunately, essential information regarding the active
management of NAFLD remains deficient and more data are
needed before the development of a practical and effec-
tive guideline. For example, clinical trials including active
prophylactic measures and studies with long-term follow-
up, especially on the durability of management, are
needed. In addition, the diagnostic accuracy of all nonin-
vasive measurements used to identify liver fibrosis seldom
exceeds 75% to 80%.54 Furthermore, most of these
measurements are not available in our daily clinical prac-
tice55,56 and may not substitute for liver biopsy in the
management of NAFLD. Therefore, effective and practical
measurements to assess the severity of NAFLD are still
lacking. Finally, interaction between NAFLD and other liver
diseases is a concern, especially in Taiwan where viral
hepatitis is rampant. For example, diabetes and obesity
have been linked to several important malignancies,
including HCC, which is a well-known complication of
chronic hepatitis in Taiwan.57 However, patients with
chronic HCV infection are usually associated with a lower
serum lipid profiles than healthy adults,58 and a clearance
of HCV may increase the risk of cardiovascular diseases in
some participants.59 Therefore, the situations are more
complicated than ever, and not just a question of treat-or-
not. Several issues remain unsolved and need further
studies, such as the impact of NAFLD on disease progressionof other liver diseases or therapy, interactions, and path-
ophysiological mechanisms.
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